Cigna Group $CI Holdings Cut by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. reduced its position in Cigna Group (NYSE:CI) by 4.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 103,338 shares of the health services provider’s stock after selling 4,777 shares during the period. Crossmark Global Holdings Inc.’s holdings in Cigna Group were worth $28,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in CI. Sawyer & Company Inc purchased a new stake in Cigna Group in the third quarter worth about $402,000. Physician Wealth Advisors Inc. boosted its position in shares of Cigna Group by 2.0% during the third quarter. Physician Wealth Advisors Inc. now owns 2,781 shares of the health services provider’s stock worth $756,000 after acquiring an additional 55 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Cigna Group by 57.2% during the third quarter. Robeco Institutional Asset Management B.V. now owns 292,602 shares of the health services provider’s stock valued at $79,538,000 after acquiring an additional 106,513 shares in the last quarter. Diversify Advisory Services LLC increased its holdings in Cigna Group by 31.1% in the 3rd quarter. Diversify Advisory Services LLC now owns 6,859 shares of the health services provider’s stock valued at $2,050,000 after acquiring an additional 1,629 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG increased its holdings in Cigna Group by 1.5% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 8,045 shares of the health services provider’s stock valued at $2,187,000 after acquiring an additional 120 shares during the last quarter. Institutional investors own 86.99% of the company’s stock.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, insider Nicole S. Jones sold 19,436 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $276.27, for a total value of $5,369,583.72. Following the completion of the sale, the insider owned 27,256 shares of the company’s stock, valued at $7,530,015.12. This trade represents a 41.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total value of $175,258.85. Following the completion of the sale, the insider owned 5,053 shares in the company, valued at approximately $1,435,304.65. The trade was a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,730 shares of company stock valued at $6,293,359 over the last ninety days. 0.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on CI shares. Robert W. Baird set a $362.00 price target on shares of Cigna Group in a research note on Friday, July 31st. Barclays raised their price objective on Cigna Group from $304.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cigna Group in a report on Thursday, August 27th. Guggenheim lifted their target price on Cigna Group from $338.00 to $361.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Jefferies Financial Group downgraded Cigna Group from a “buy” rating to a “hold” rating and decreased their target price for the stock from $336.00 to $307.00 in a research report on Tuesday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $338.24.

Cigna Group Price Performance

Shares of Cigna Group stock opened at $304.74 on Thursday. The stock has a market cap of $80.53 billion, a price-to-earnings ratio of 9.74, a price-to-earnings-growth ratio of 1.03 and a beta of 0.29. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.76 and a current ratio of 0.76. The stock has a 50 day moving average price of $280.49 and a 200-day moving average price of $282.73. Cigna Group has a one year low of $239.51 and a one year high of $311.34.

Cigna Group (NYSE:CI) last released its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share for the quarter, beating the consensus estimate of $7.60 by $0.18. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%. The company had revenue of $71.56 billion for the quarter, compared to analyst estimates of $70.14 billion. During the same quarter in the prior year, the firm posted $7.20 EPS. Cigna Group’s quarterly revenue was up 6.7% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Equities analysts expect that Cigna Group will post 30.50 EPS for the current year.

About Cigna Group

The Cigna Group (NYSE: CI) is a global health services company that provides insurance coverage, health care benefits and related services. Its operations are primarily organized through Cigna Healthcare, which offers medical, pharmacy, dental, behavioral health and other benefit programs to employers, government organizations and individuals, primarily in the United States.

The company also operates Evernorth Health Services, a health services platform that includes pharmacy benefit management, specialty pharmacy, care management and health-care delivery capabilities.